Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates

分组1 - Nurix Therapeutics reported a quarterly loss of $0.82 per share, which was better than the Zacks Consensus Estimate of a loss of $0.84, but worse than a loss of $0.75 per share a year ago, indicating an earnings surprise of +2.88% [1] - The company posted revenues of $13.58 million for the quarter, missing the Zacks Consensus Estimate by 24.12%, compared to revenues of $13.28 million in the same quarter last year [2] - The stock has gained approximately 2.3% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.80 on revenues of $15.4 million, and for the current fiscal year, it is -$3.06 on revenues of $81.89 million [7] - The Medical - Biomedical and Genetics industry, to which Nurix Therapeutics belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]